VMQ StocksFor the value investor looking to harness academic research in
an actively managed portfolio
Bits and BipsNewsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company’s IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
Financial Summary
Share Statistics
DCOY
Industry Median
Percentile (All Stocks)
Market Cap (Mil)
$2.1
$286.3
1%
Shares Out (Mil)
0.5
54.2
3%
Institutional Ownership
62.7%
92.8%
40%
Float (Mil)
0.5
39.7
1%
Beta
0.58
0.94
34%
Avg Daily Volume (000s)
24
534
21%
Price Change (52-week)
(95.2%)
58.7%
2%
Growth
DCOY
Industry Median
Percentile (All Stocks)
Sales (5yr)
na
13.6%
na
Net Income (5yr)
(11.1%)
(10.1%)
28%
EPS (5yr)
na
16.0%
na
Dividends (5yr)
na
0.0%
0%
Cash Flow (5yr)
na
(15.6%)
na
Estimates
Qtrly
Current Fiscal Year
Next Fiscal Year
# of Estimates
na
na
na
Current EPS
na
na
na
Month Ago EPS
na
na
na
# Rev Up
na
na
na
# Rev Down
na
na
na
Three Months Ago EPS
na
na
na
Year/Year Chg
na
na
na
Financials
DCOY
Industry Median
Percentile (All Stocks)
Sales (TTM) (Mil)
$0
$37
0%
Net Income (TTM) (Mil)
($14)
($43)
26%
EPS (TTM)
($40.396)
($1.400)
1%
Operating Cash Flow (TTM) (Mil)
($8)
($31)
21%
Net Cash Flow (TTM) (Mil)
na
$2
na
Long-Term Debt (Q1) (Mil)
$0
$4
0%
Enterprise Value (Q1) (Mil)
($6)
$160
2%
Valuation
DCOY
Industry Median
Percentile (All Stocks)
P/B
0.40
2.77
6%
P/E
na
19.1
na
Dividend Yield
0.0%
0.0%
0%
PEG (5yr hist)
na
1.0
na
Ratios
DCOY
Industry Median
Percentile (All Stocks)
Gross Margin
(718.1%)
64.2%
0%
Net Margin
na
(75.9%)
na
ROA
(278.0%)
(47.3%)
1%
ROE
(827.8%)
(55.0%)
0%
Liabilities to Assets
52.0%
29.6%
45%
F-Score
2
2
na
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
DCOY meetings the criteria of 1 screen:
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors